New Hope for Migraine Patients

Video

The FDA has approved a new drug for the prevention of migraines. Will the injectable treatment help reduce the number of days of migraine headaches?

The FDA has approved a new drug for the prevention of migraines. Aimovig (erenumab) was evaluated in 3 separate clinical trials and found to be effective in reducing the number of migraines headaches by 1 to 2.5 episodes a month in patients compared with placebo.

The drug helps prevent migraines by interacting with a protein called CGRP (calcitonin gene related peptide). The most common adverse effects are injection site irritation and constipation. The drug is administered monthly by self-injection. The US list price of Aimovig is $575 for once monthly 70 mg or 140 mg single-use prefilled SureClick® autoinjectors, or $6900 annually.

Although not a cure, the medication offers hope and some relief for the more than 4 million people afflicted with migraine headaches and the physical and emotional pain they cause.

Related content: CGRPs: New Help in Migraine Prophylaxis?

Reference

1. US Food and Drug Administration. FDA approves novel preventive treatment for migraine. May 17, 2018. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm608120.htm. Accessed June 7, 2018.

Related Videos
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
Amaal Starling, MD, FAHS, FAAN
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
Andrea S. Synowiec, DO, FAAN, the system vice chair for the department of neurology at Allegheny Health Network
© 2024 MJH Life Sciences

All rights reserved.